Phaseline

Targets › MITOMYCIN

MITOMYCIN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology.

Open in Phaseline: the race on MITOMYCIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
UroGen PharmaUGN-103
Mitomycin delivered via intravesical thermosensitive hydrogel
MITOMYCINPhase 3Bladder Cancer–

Conditions

Bladder Cancer (1)

Modalities

small molecule (1)

Companies

UroGen Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.